Ken Griffin Macrogenics Inc Put Options Transaction History

Citadel Advisors LLC

7 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2024 Aug 14, 2024	BUY	$3.31 - $18.51 $27,804 - $155,484	8,400 Added 29.47%	36,900 $156,000
Q1 2024 May 15, 2024	BUY	$9.77 - $21.47 $228,618 - $502,398	23,400 Added 458.82%	28,500 $419,000
Q4 2023 Feb 14, 2024	BUY	$4.48 - $10.11 $5,376 - $12,132	1,200 Added 30.77%	5,100 $49,000
Q3 2023 Nov 14, 2023	SELL	$4.48 - $6.19 $17,024 - $23,522	-3,800 Reduced 49.35%	3,900 $18,000
Q2 2023 Aug 14, 2023	BUY	$4.62 - $7.54 $13,398 - $21,866	2,900 Added 60.42%	7,700 $41,000
Q1 2023 May 15, 2023	SELL	$4.82 - $7.24 $14,460 - $21,720	-3,000 Reduced 38.46%	4,800 $34,000
Q4 2022 Feb 14, 2023	BUY	$3.34 - $6.98 $26,052 - $54,444	7,800 New	7,800 $52,000

154

60.6M

218K

259K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $203M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.